Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.…
Cerus Corporation to Participate in Upcoming Investor Conferences
Cerus (NASDAQ: CERS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 261 employees.
The shares were at 1.850 USD on 20 November 2026, up 8.2% over 52 weeks. Its 52-week range is 1.470 USD to 3.470 USD: the price is 46.7% below the high and 25.9% above the low.
Its market capitalisation is 373.62M USD.
Cerus reports return on equity of -24.3%, an operating margin of -1.1% and revenue up 9.5% year over year.
Its debt exceeds its cash by 17.85M USD, a debt-to-equity ratio of 1.51. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 4 analysts cover the stock; their mean price target of 5.125 USD is 177.0% above the current price. The next earnings report is expected on 1 March 2027.